A recent meta-analysis of CD22 CAR-T clinical trials for relapsed B cell acute lymphoblastic leukemia (B-ALL) found a mean complete response rate of 75%, and this was raised to 87% when combined with CD19-targeted CAR.40 The gene discussed is CD22; the disease is B-cell acute lymphoblastic leukemia.